10-Q: RMTG Q2 Revenue Jumps Amidst Deepening Debt Defaults
Sentiment:
Quarterly Report
Regenerative Medical Technology Group Inc. reported significant revenue growth in Q2 2025, but faces severe financial distress with a substantial accumulated deficit and numerous defaulted loans, raising going concern doubts.
Delay expectedThe opening of the Dubai, UAE clinic, originally scheduled for September 2025, has been pushed to Spring 2026.A $100,000 prepaid inventory product did not pass required testing and was not delivered within the agreed timeframe, leading the company to seek a refund.
Capital raiseThe company entered into a Promissory Debenture on April 9, 2025, for $1,375,000 (net $1,100,000 advanced) which included the issuance of one share of Series CC Preferred Stock and a ten-year warrant to purchase up to 999 shares of Series CC Preferred Stock.Subsequent to the reporting period (August 14, 2025), the company entered into Extension Agreements for several defaulted senior secured promissory notes, issuing new warrants to investors as consideration.Management explicitly states the intention to fund operations through debt and/or equity financing arrangements and plans to seek additional financing in a private equity offering.
Worse than expectedDespite significant revenue growth and a reduction in net loss, the company's financial position deteriorated with an increased accumulated deficit and working capital deficit.Cash flow from operating activities turned negative, indicating that core operations are consuming cash rather than generating it.The company is in default on approximately $16.1 million in principal debt, with an additional $11.4 million in accrued interest, highlighting severe liquidity and solvency issues.Management explicitly states that the company does not have sufficient cash to operate for the next twelve months and raises substantial doubt about its ability to continue as a going concern.Identified material weaknesses in internal control over financial reporting indicate significant deficiencies in financial oversight and reporting processes.
Summary
- Revenue for the three months ended June 30, 2025, increased by 23.97% to $983,518, up from $793,329 in the same period of 2024.
- Net loss for the three months ended June 30, 2025, decreased to $1,305,785, compared to a net loss of $2,076,620 in the prior year period.
- For the six months ended June 30, 2025, revenue surged by 45.80% to $2,347,859, up from $1,610,363 in 2024.
- Net loss for the six months ended June 30, 2025, was $2,065,825, a significant reduction from $4,037,640 in the comparable 2024 period.
- The company reported an accumulated deficit of $69,618,927 and a working capital deficit of $28,630,295 as of June 30, 2025.
- Total liabilities increased to $33,508,078 as of June 30, 2025, from $31,178,101 at December 31, 2024.
- Cash and cash equivalents increased to $1,614,254 as of June 30, 2025, from $1,165,820 at December 31, 2024.
- Operating activities used $540,984 in cash for the six months ended June 30, 2025, a reversal from cash provided of $198,364 in the prior year period.
- The company has approximately $16.1 million in principal value of secured and unsecured promissory notes currently in default, with an additional $11.4 million in accrued interest on these defaulted notes.
- The planned opening of the Dubai, UAE clinic has been delayed from September 2025 to Spring 2026.
- A $100,000 prepaid inventory product did not pass required testing and was not delivered, with the company seeking a refund.
Sentiment
Score: 2
Explanation: While revenue growth and reduced net loss are positive, the company's severe financial distress, including a massive accumulated deficit, significant debt defaults, negative operating cash flow, and explicit going concern doubts, overshadows any operational improvements. The internal control weaknesses and product delivery issues further compound the negative outlook, indicating high risk and instability.
Positives
- Revenue increased by 23.97% for the three months and 45.80% for the six months ended June 30, 2025, driven by marketing efforts, increased lead generation, and the Cancun facility.
- Net loss significantly reduced by 37.12% for the three months and 48.84% for the six months ended June 30, 2025, compared to the same periods in 2024.
- Interest expense decreased by 43.32% for the three months and 47.55% for the six months ended June 30, 2025, primarily due to a decrease in amortization of discount and finance charges.
- Patient procedures revenue more than doubled for the six months ended June 30, 2025, reaching $1,029,450 from $471,239 in 2024.
- The company is actively expanding its clinical network with confirmed plans for four new clinic locations in Indonesia, Puerto Rico, Santiago (Chile), and Lisbon (Portugal) in 2025.
- Manufacturing scale-up is underway with the Cancun facility transitioning to full-scale production in 2025, and a soft opening for a new Advanced Cell Therapy Manufacturing Lab in Cancun scheduled for September 2025.
- New product lines, including innovative Cellgenic peptides, were introduced in August 2024, expected to further increase revenue.
- Strategic initiatives are in place to enhance educational programs, including an expanded online learning platform and a major international congress in Q4 2025.
Negatives
- The company has incurred losses since inception, resulting in an accumulated deficit of $69,618,927 as of June 30, 2025.
- A substantial working capital deficit of $28,630,295 as of June 30, 2025, indicates significant liquidity challenges.
- Numerous promissory notes, totaling approximately $16.1 million in principal and $11.4 million in accrued interest, are currently in default.
- Cash used in operating activities for the six months ended June 30, 2025, was $540,984, a negative shift from cash provided in the prior year.
- The company does not have sufficient cash to operate its business at the current level for the next twelve months.
- Operating expenses increased by 12.83% for the three months and 16.25% for the six months ended June 30, 2025, primarily due to increased professional fees and advertising/marketing.
- Equipment sales significantly decreased for the six months ended June 30, 2025, to $8,435 from $102,060 in 2024.
- Identified material weaknesses in internal control over financial reporting, including lack of written documentation, inadequate communication, and improper accounting for a prior acquisition.
Risks
- Substantial doubt about the company's ability to continue as a going concern due to accumulated losses and working capital deficit.
- Inability to service outstanding secured and unsecured loans, many of which are in default, leading to potential demands for payment and asset seizure by lenders.
- Failure to obtain adequate additional financing on a timely basis and on acceptable terms to fund operations and strategic objectives.
- Uncertainty of profitability given the company's history of losses.
- Risks related to legislative or regulatory changes concerning regenerative medicine and therapies.
- Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
- Competition within the regenerative medicine industry.
- Cybersecurity concerns affecting operations and data integrity.
- Reliance on estimates and assumptions in financial statement preparation, which could differ from actual results.
- Risk of product failure or non-delivery, as evidenced by the $100,000 prepaid inventory product that failed testing.
Future Outlook
The company's operational strategy for 2025 focuses on translating market position and technological advantages into sustainable revenue growth and expanded market share. It anticipates accelerated growth through clinic network expansion, manufacturing scale-up, and market penetration in key regions including Southeast Asia, Latin America, and potentially North America. The company plans to launch a minimum of four new clinic locations in Indonesia, Puerto Rico, Santiago (Chile), and Lisbon (Portugal) in 2025, with additional planned clinics in Mexico, the United States, and other international markets. The Cancun manufacturing facility is expected to transition to full-scale production in 2025, with a new Advanced Cell Therapy Manufacturing Lab soft opening in September 2025. Product line diversification will continue with new offerings in peptides, exosome therapies, and biologics. Educational programs through ISSCA will be enhanced, including an online learning platform and a major international congress in Q4 2025. Strategic entry into the U.S. market is planned as regulatory environments evolve. The company expects accelerating revenue growth, margin expansion, and enhanced profitability, supported by disciplined capital allocation and evaluation of strategic acquisition opportunities. However, the company acknowledges it will require additional funding to finance growth and achieve strategic objectives.
Management Comments
- "We believe stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management."
- "We expect that our revenues will increase in future quarters as a result of our ongoing marketing and brand awareness campaigns, training seminars, lectures and other efforts we engage in that expand our presence in the industry and provide us with more opportunities to sell our products."
- "We expect our overall operating expenses to increase into 2025 as we further implement our business plan."
- "If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes, and we will be unable to repay the loans. If this happens, we could go out of business."
- "Based upon the current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months."
- "We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements."
- "There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired, and we could go out of business."
Industry Context
The company operates in the rapidly evolving regenerative medicine industry, focusing on stem cell therapy, exosomes, and peptides. This sector is characterized by significant clinical research, patient demand for alternative treatments, and evolving regulatory landscapes, particularly in markets like the U.S. The company's strategy of combining clinical research with manufacturing and commercialization of cell therapy products, alongside physician training and direct patient care, positions it to capture value across the regenerative medicine ecosystem. Its expansion into new geographic markets like Southeast Asia, Latin America, and the Middle East aligns with the global growth trends in this specialized healthcare segment.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President, Chief Executive Officer, Chief Financial Officer, Secretary and Director | NA | David Christensen | 2022-01-01 | Compensation agreement for services, including issuance of Series DD Preferred Stock. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | Identified material weaknesses in internal control over financial reporting, including lack of written documentation of policies and procedures, inadequate communication for proper transaction recording, and failure to account for the GSCG acquisition using the full purchase accounting method. | 2025-06-30 | These weaknesses are reasonably likely to adversely affect the company's ability to record, process, summarize, and report financial information, impacting the reliability of financial reporting. Management plans remedial action in fiscal year 2025. |
| Preferred Stock Designation Termination | Board of Directors approved and filed Certificates of Withdrawal of Certificate of Designations relating to Series BB and Series CC Preferred Stock, terminating their designation as no shares were outstanding. | 2024-02-01 | Streamlines capital structure by removing unused preferred stock series. |
| New Preferred Stock Designation | Created a newly designated Series CC Convertible Preferred Stock (1,000 shares authorized, $0.001 par value) with specific conversion terms (conversion into common stock by dividing common shares outstanding by 1,000) and no voting or dividend rights. | 2025-04-10 | Introduces a new class of preferred stock for financing purposes, potentially dilutive upon conversion, but without direct voting power or dividend obligations. |
Legal Proceedings
- To the company's knowledge, there are no pending or threatened legal actions, suits, proceedings, inquiries, or investigations that could have a material adverse effect on the company.
Related Party Transactions
- Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer, and Secretary, was compensated $45,000 for consulting services through Enterprise Technology Consulting (100% owned by him) during the six months ended June 30, 2025.
- Benito Novas's brother, sister, and nephew provided marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $167,775 in aggregate as consultants during the six months ended June 30, 2025.
Stakeholder Impact
- **Shareholders:** Face significant risk of value erosion due to severe financial distress, accumulated deficit, and potential dilution from future capital raises and warrant exercises. The going concern doubt poses an existential threat to their investment.
- **Creditors/Lenders:** Many existing lenders are impacted by defaulted notes, with substantial principal and accrued interest outstanding. While some debt extensions have been granted, the risk of non-repayment remains high, potentially leading to asset seizure for secured creditors.
- **Employees:** The company's financial instability and going concern issues could impact job security and future compensation. However, the expansion plans suggest potential for new hires in growth areas.
- **Customers (Physicians/Patients):** Continued expansion of clinics and product lines could benefit customers by increasing access to regenerative medicine therapies and training. However, the company's financial instability could pose risks to long-term service continuity or product availability.
- **Suppliers:** The company's liquidity issues and debt defaults could pose payment risks to suppliers, potentially affecting supply chain relationships.
Next Steps
- Launch a minimum of four new clinic locations in Indonesia, Puerto Rico, Santiago (Chile), and Lisbon (Portugal) in 2025.
- Transition the Cancun manufacturing facility to full-scale production in 2025.
- Host a soft opening of the new Advanced Cell Therapy Manufacturing Lab in Cancun during the September 2025 ISSCA Global Summit.
- Continue product line diversification with new offerings in peptides, exosome therapies, and biologics.
- Enhance educational programs, including deploying a comprehensive online learning platform and hosting a major international congress in Q4 2025.
- Strategically enter new geographic markets, particularly North America, as regulatory environments evolve.
- Implement comprehensive operational efficiency initiatives, including process standardization, technology integration, workforce development, and continuous improvement.
- Continue investment in research and development focusing on exosome characterization, combination therapy protocols, tissue-specific regeneration, biomarker identification, and delivery system innovations.
- Seek additional funding through debt and/or equity markets, including a private equity offering, to finance operations and growth.
- Take remedial action to address identified material weaknesses in internal control over financial reporting during the fiscal year ended December 31, 2025.
- Secure a refund for the $100,000 prepaid inventory product that failed testing.
Key Dates
| Date | Description |
|---|---|
| 1999 | Company originally organized as Spectrum Ventures, LLC in Washington State. |
| 2002 | Company changed its name to Nxtech Wireless Cable Systems, Inc. |
| 2007-11 | Company changed its name to Oriens Travel & Hotel Management Corp. |
| 2014-11 | Company changed its name to Pure Hospitality Solutions, Inc. |
| 2016-11-16 | Company entered into Agreement and Plan of Merger with Meso Numismatics Corp. (Meso). |
| 2017-08-04 | Acquisition of Meso Numismatics Corp. completed. |
| 2017-09-04 | Company suspended booking operations (Oveedia) to focus on numismatic business. |
| 2018-07-02 | Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split. |
| 2018-09 | Company changed its name to Meso Numismatics, Inc. |
| 2018-10-16 | FINRA market effective date for new ticker symbol MSSV. |
| 2019-01-08 | Acquisition of 2018 Jaguar F-Pace from Benito Novas for $45,000, assuming related auto loan. |
| 2019-11-25 | Company elected to exchange Series BB Preferred Stock for convertible notes or promissory notes. |
| 2019-12-03 | Melvin Pereira converted 18,500 Series BB preferred shares to common stock and exchanged 6,500 shares for a $7,800 promissory note. |
| 2020-11-17 | Agreement with a lender for $400,000 promissory note, granting perpetual 7.75% of Global Stem Cell Group revenues. |
| 2020-12-07 | Company exchanged $5,379,624 of debt for promissory notes and cashless warrants to purchase 15,000,000 common shares. |
| 2020-12-09 | Company entered into a Promissory Debenture for $110,000 with cashless warrants to purchase 1,000,000 common shares. |
| 2021-01-06 | Company entered into a Promissory Debenture for $1,000,000 with cashless warrants to purchase 10,000,000 common shares. |
| 2021-06-22 | Company entered into a Promissory Debenture for $11,600,000 with cashless warrants to purchase 70,000,000 common shares. |
| 2021-07-02 | Final payment of $50,000 made for the acquisition of Global Stem Cells Group Inc. |
| 2021-08-18 | Company completed acquisition of Global Stem Cells Group Inc. |
| 2021-09-20 | Company entered into a Promissory Debenture for $1,100,000 with cashless warrants to purchase 7,500,000 common shares. |
| 2021-11-03 | Company paid $8,200,000 in cash to an escrow account for Lans Holdings Inc. stock repurchase. |
| 2021-12-30 | Modified terms of Promissory Debentures from July 13, 2020 ($6,000) and July 15, 2020 ($84,000) by issuing new notes. |
| 2022-01-16 | Cancun lease with HELLIMEX, S.A. DE CV began. |
| 2022-05 | Cancun facility inaugurated and accredited. |
| 2022-10-28 | Company agreed to sell 100% interest in Meso Numismatics to Mr. Melvin Pereira. |
| 2023-11-20 | Company and two lenders agreed to terminate a 2020 Secured Note ($2,506,827) in exchange for $300,000 and new notes. |
| 2024-01-15 | Original Cancun lease with HELLIMEX, S.A. DE CV ended. |
| 2024-01-16 | New Cancun lease with RIVIERA MAYA, S.A. DE C.V began due to expansion. |
| 2024-02-01 | Board of Directors approved and filed Certificates of Withdrawal for Series BB and Series CC Preferred Stock designations. |
| 2024-02-29 | Company issued 45,030 common shares for conversion of convertible notes. |
| 2024-08 | Company introduced new line of innovative Cellgenic peptides. |
| 2024-10-18 | FINRA provided market effective date for name and symbol change to Regenerative Medical Technology Group Inc. (RMTG). |
| 2024-10-21 | New name Regenerative Medical Technology Group Inc. and symbol RMTG became effective. |
| 2024-12-31 | Company signed a five-year extension for the Cancun lease, commencing on this date. |
| 2025-04-09 | Company entered into a Promissory Debenture for $1,375,000 with a lender, including issuance of one Series CC Preferred Stock share and warrants. |
| 2025-04-10 | Company filed certificate of designation preferences for newly created Series CC Convertible Preferred Stock with Nevada Secretary of State. |
| 2025-06-30 | End of the quarterly period covered by this report. |
| 2025-08-14 | Company entered into Extension Agreements for several defaulted senior secured promissory notes (totaling $15,572,797 principal) to July 31, 2026, issuing new warrants and increasing interest rates for some. |
| 2025-08-14 | Company notified that a $100,000 prepaid inventory product failed testing and was not delivered, seeking a refund. |
| 2025-08-17 | Date of common stock outstanding count (12,538,968 shares). |
| 2025-08-19 | Date of signing of the Form 10-Q report. |
| 2025-09 | Cellgenic to host soft opening of new Advanced Cell Therapy Manufacturing Lab in Cancun during ISSCA Global Summit. |
| 2026-01-15 | Current Cancun lease with RIVIERA MAYA, S.A. DE C.V ends. |
| 2026-03-20 | Expected opening of Dubai, UAE clinic (Spring 2026). |
| 2026-07-31 | Extended Maturity Date for several defaulted senior secured promissory notes. |
| 2029-12-31 | End date of the five-year extension for the Cancun lease. |
Recommendation
strong sellDespite reported revenue growth and a reduction in net loss, the company's financial foundation is extremely precarious. It operates with a massive accumulated deficit and a significant working capital deficit, explicitly stating it lacks sufficient cash for the next twelve months. The presence of approximately $16.1 million in principal debt and $11.4 million in accrued interest that are in default, coupled with management's 'substantial doubt' about its ability to continue as a going concern, indicates severe insolvency risk. While debt restructuring talks and new financing are mentioned, there's no assurance of success. The identified material weaknesses in internal controls further undermine confidence in financial reporting. For a seasoned investor, the fundamental financial instability and high risk of business failure far outweigh any operational positives, making a 'strong sell' recommendation appropriate.
Keywords
Regenerative Medicine, Stem Cell Therapy, Biotechnology, Medical Technology, SEC Filing, Financial Report, Quarterly Results, Debt Default, Going Concern, Clinic Expansion, Cellgenic, Peptides, Exosomes, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.